Drugs / GSK3745417
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05424380 | Sep 2022 → Mar 2024 | acute myeloid leukemia | GlaxoSmithKline | Terminated | No outcome recorded |
| Phase 1 | NCT03843359 | Mar 2019 → Apr 2024 overdue | neoplasm | GlaxoSmithKline | Active not recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | GSK3745417 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03843359 ↗ |
| Route | Intravenous | “Intravenous GSK3745417” NCT05424380 ↗ |